Bladder Cancer News and Research

Latest Bladder Cancer News and Research

EC grants orphan medicinal product designation to Allos' pralatrexate for Hodgkin lymphoma

Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of Hodgkin lymphoma (HL). The Company is currently investigating pralatrexate in a number of ongoing studies, including a Phase 2 clinical study in patients with relapsed or refractory non-Hodgkin lymphoma or Hodgkin lymphoma.

15 Oct 2010

FDG positron emission tomography allows early diagnosis of gall bladder cancer

Researchers at the University of Granada and the Department of Nuclear Medicine, Hospital Virgen de las Nieves at Granada found that the metabolic imaging diagnosis technique based on the analysis of a structural analog of glucose labeled with a positron-emitting compound (18F) allows early diagnosis of gall bladder cancer, a relatively rare disease with high mortality rates among most patients suffering from it.

15 Oct 2010

Study demonstrates chitosan/IL-12 is an effective anti-tumor immunotherapy

A new study by a University of Arkansas biomedical engineer and his colleagues at the National Cancer Institute demonstrates further promise for chitosan/interleukin-12 as an effective anti-tumor immunotherapy.

13 Oct 2010

$Pazopanib shows promise in phase-2 trial for relapsed/refractory urothelial cancer$

Pazopanib shows promise in phase-2 trial for relapsed/refractory urothelial cancer

An ongoing Phase-II trial investigating a new, targeted therapy for metastatic urothelial cancer has generated promising early results, Italian researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.

11 Oct 2010

Miller-Mccune examines impact of limited access to schistosomiasis drug in Africa

Miller-McCune examines the limited access populations living in Africa have to the schistosomiasis drug praziquantel the only commercially available treatment for the disease.

6 Oct 2010

Tengion presents Neo-Kidney Augment development program at ISCT Symposium

Tengion, Inc. presented new research data yesterday in a podium presentation at the 2nd Annual Symposium on Stem Cell Translation of the International Society for Cellular Therapy (ISCT) in San Francisco. The presentation highlighted new results from Tengion's Neo-Kidney Augment development program demonstrating success with an autologous cellular therapy approach to kidney regeneration in a rodent model of obesity, diabetes and hypertension.

30 Sep 2010

microRNA may provide quick diagnosis of bladder cancer

Scientists may have discovered a way to diagnose bladder cancer at its earliest and, therefore, most treatable stages by measuring the presence or absence of microRNA using already available laboratory tests.

29 Sep 2010

Genta commences new tesetaxel Phase 2 clinical trial in advanced bladder cancer

Genta Incorporated today announced that the Company has initiated a new Phase 2 clinical trial of tesetaxel in patients with advanced bladder cancer. Tesetaxel is the leading oral taxane in clinical development. The new trial will be conducted at Memorial Sloan-Kettering Cancer Center, New York, NY, the Kimmel Cancer Center at Jefferson University, Philadelphia, PA, and at least one site in the EU.

24 Sep 2010

High selenium intake associated with lower rates of bladder cancer in women

Scientists in Spain have found that adding a can of tuna or other fish to our shopping lists could help protect us against bladder cancer.

23 Sep 2010

AACR to host fourth International Conference on Molecular Diagnostics

The American Association for Cancer Research will host its Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development from Sept. 27-30, 2010, at the Sheraton Denver Downtown in Denver, Colo.

22 Sep 2010

FDA reviews Actos drug for bladder cancer risk

The U.S. Food and Drug Administration today announced it has begun a safety review of the diabetes drug Actos (pioglitazone), after receiving preliminary results from a long-term observational study designed to evaluate the risk of bladder cancer associated with use of this drug.

18 Sep 2010

Johns Hopkins offers sources who can answer queries on prostrate cancer

September 19-25 is National Prostate Cancer Awareness Week. If you are planning a story on prostate cancer, a disease that's diagnosed in more than 200,000 American men each year, please consider calling on experts from the Johns Hopkins Brady Urological Institute.

16 Sep 2010

Molecule in cells predicts success of radiotherapy in individual bladder cancer patients

CANCER RESEARCH UK scientists have identified a molecule in cells which could predict the success of radiotherapy to treat individual bladder cancer patients, reveals research published in Cancer Research1 today (Wednesday).

15 Sep 2010

Cell-enriched primary renal cells improve survival and augment kidney function in CKD rodents

Tengion, Inc., a leader in regenerative medicine, announced today the publication of a key study in the American Journal of Physiology Renal Physiology by researchers at Tengion. In the study, rodents with chronic kidney disease (CKD) were treated with healthy kidney cells to catalyze the regeneration of functional kidney tissue and delay disease progression, as evidenced by extended survival, improved kidney filtration, and reduced severity of kidney tissue pathology.

14 Sep 2010

Genotoxic effects of exposure to disinfection by-products in indoor swimming pools

Swimming in indoor chlorinated pools may induce genotoxicity (DNA damage that may lead to cancer) as well as respiratory effects, but the positive health effects of swimming can be maintained by reducing pool levels of the chemicals behind these potential health risks, according to a new study published in a set of three articles online September 12 ahead of print in the peer-reviewed journal Environmental Health Perspectives (EHP).

13 Sep 2010

Johns Hopkins added as second clinical trial site in Tengion Neo-Urinary Conduit Phase I clinical trial

Tengion, Inc., a leader in regenerative medicine, announced today it has added The Johns Hopkins Hospital in Baltimore, Maryland as a second clinical trial site for its Phase I clinical trial of the Company's lead product candidate, the Tengion Neo-Urinary Conduit™, in bladder cancer patients requiring bladder removal.

10 Sep 2010

Bioniche reduces net loss per share from $0.15 in fiscal 2009 to $0.02 in fiscal 2010

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its 2010 fiscal year ended June 30, 2010.

10 Sep 2010

Professional painters face higher risk of developing bladder cancer

A new study by the International Agency for Research on Cancer (IARC) has provided further evidence that professional painters may face a higher risk of developing bladder cancer than the general population.

9 Sep 2010

High selenium intake associated with decreased risk of bladder cancer

According to results of a study published in the September issue of Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research, selenium intake is associated with decreased risk of bladder cancer.

2 Sep 2010

'Yakult' effective in reducing acute diarrhea in young children: Study

YAKULT HONSHA CO., LTD. announced on August 20 that its collaborative study on the incidence of acute diarrhea with the National Institute of Cholera and Enteric Diseases in Kolkata, India, showed that daily intake of "Yakult" is efficacious in reducing the incidence of diarrhea in young children.

21 Aug 2010

Bladder Cancer News and Research

Latest Bladder Cancer News and Research

EC grants orphan medicinal product designation to Allos' pralatrexate for Hodgkin lymphoma

FDG positron emission tomography allows early diagnosis of gall bladder cancer

Study demonstrates chitosan/IL-12 is an effective anti-tumor immunotherapy

Pazopanib shows promise in phase-2 trial for relapsed/refractory urothelial cancer

Miller-Mccune examines impact of limited access to schistosomiasis drug in Africa

Tengion presents Neo-Kidney Augment development program at ISCT Symposium

microRNA may provide quick diagnosis of bladder cancer

Genta commences new tesetaxel Phase 2 clinical trial in advanced bladder cancer

High selenium intake associated with lower rates of bladder cancer in women

AACR to host fourth International Conference on Molecular Diagnostics

FDA reviews Actos drug for bladder cancer risk

Johns Hopkins offers sources who can answer queries on prostrate cancer

Molecule in cells predicts success of radiotherapy in individual bladder cancer patients

Cell-enriched primary renal cells improve survival and augment kidney function in CKD rodents

Genotoxic effects of exposure to disinfection by-products in indoor swimming pools

Johns Hopkins added as second clinical trial site in Tengion Neo-Urinary Conduit Phase I clinical trial

Bioniche reduces net loss per share from $0.15 in fiscal 2009 to $0.02 in fiscal 2010

Professional painters face higher risk of developing bladder cancer

High selenium intake associated with decreased risk of bladder cancer

'Yakult' effective in reducing acute diarrhea in young children: Study

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Bladder Cancer News and Research

Latest Bladder Cancer News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in